Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines
Introduction
Ovarian cancer is the most lethal cancer among gynaecological tumours and is the fifth most frequent cause of cancer deaths among women. At the beginning of treatment, ovarian cancer is among the most chemosensitive malignancies. However, during treatment, most patients develop drug resistance leading to the ineffectiveness of further treatment (Hennessy et al., 2009). The first-line treatment includes taxane/platinum-based chemotherapy (Parmar et al., 2003). Unfortunately, most of the ovarian cancer patients with good response to first-line treatment will experience recurrence of the disease. In the second-line treatment, taxane derivatives as well as cisplatin (CIS), topotecan (TOP), doxorubicin (DOX) and gemcitabine are mainly used (Pfisterer et al., 2006, Mutch et al., 2007, Ferrandina et al., 2008, Sehouli et al., 2008, Mahner et al., 2015).
The failure of chemotherapy results from inherent or acquired chemotherapy drug resistance. At least tens of proteins are responsible for the drug resistance of cancer cells. However, the most important and widespread mechanism of drug resistance is the active removal of the cytostatic drugs from the cancer cells by transport proteins. These transport proteins belong to ABC family of transmembrane transporters and use the energy from the hydrolysis of ATP to remove drugs from the cell (Stavrovskaya, 2000). This form of drug resistance is called multiple drug resistance (MDR). The most important ABC protein is P-glycoprotein (P-gp), which is encoded by the ABCB1 (multidrug resistance protein 1-MDR1) gene (Leonard et al., 2003). P-gp overexpression has been reported in more than 50% of cancers with the MDR phenotype (Choi, 2005). Another important MDR protein is the breast cancer resistance protein, BCRP (ABCG2). This drug transporter confers resistance to many cytostatic drugs, including mitoxantrone and TOP (Maliepaard et al., 1999, Robey et al., 2007). Expression of both proteins was also observed by us in drug-resistant ovarian cancer cell lines (Januchowski et al., 2013a).
Aldehyde dehydrogenases (ALDHs) are a family of NAD(P)+-dependent enzymes involved in detoxifying a wide variety of endogenous and exogenous aldehydes to their corresponding weak carboxylic acids (Sladek, 2003). The ALDH1A1 isoform is involved in metabolism of vitamin A (retinol) and oxidizes retinaldehyde to retinoid acid (RA) (Duester et al., 2003). This is related to its role in cell differentiation. The results of many studies indicate that ALDH1A1 is involved in the biology of normal stem cells (NSCs) as well as cancer stem cells (CSCs) and that ALDH1A1 plays a role in the drug resistance of these cells (Ma and Allan, 2011, Januchowski et al., 2013b). Sun et al. conducted a proteomics analysis study and showed that one of the proteins overexpressed in the A549-Taxol lung cancer cell line, which is resistant to paclitaxel, was ALDH1 (Sun et al., 2011). In 2009, Tanei et al., using immunohistochemical staining of breast tumour tissue obtained before and after neoadjuvant chemotherapy (DOX + paclitaxel (PAC)) demonstrated that tissue from patients with poor response to chemotherapy had an increased level of ALDH1 expression. Furthermore, this expression increased after chemotherapy (Tanei et al., 2009). It was observed that patients with pancreatic cancer had ALDH-negative primary tumours but ALDH-positive metastases (Rasheed et al., 2010). Expression of ALDH1 has also been reported in ovarian cancers and ovarian cancer cell lines (Landen et al., 2010, Silva et al., 2011, Wang et al., 2012). Furthermore, taxane and platinum resistance correlated with ALDH1A1 expression in ovarian cancer cell lines (Landen et al., 2010). The role of ALDH1 in resistance to cytostatic drugs was also confirmed in breast cancer. In 2011, Croker et al., using a cell sorter, isolated cells with overexpression of ALDH from MDA-MB-231 and MDA-MB-468 breast cancer cell lines (Croker and Allan, 2012). These cells demonstrated significant resistance to DOX and PAC in comparison to cells with low ALDH expression. All of these results suggest that cancer cells with overexpression of ALDH1 (ALDH1A1) can be responsible for the development of drug resistance both in vivo and in vitro.
Currently, two major, contrasting models exist to explain the development of cancer drug resistance at the cellular level. The classical theory of therapy resistance involves cells developing acquired resistance following a particular therapy (Gerlinger and Swanton, 2010, Greaves and Maley, 2012). The CSCs model postulates that a small population of cancer cells is intrinsically resistant to chemotherapy and that these cells are responsible for drug resistance in primary tumours as well as for metastasis (Clevers, 2011). One of the characteristic features of CSCs in the context of drug resistance is the high expression levels of ABC transporters (Moitra et al., 2011) and other self-protection mechanisms (Alison et al., 2012). The other characteristic features of these cells are high expression levels of ALDH enzymes (especially the ALDH1A1 and/or ALDH3A1 isoforms) (Alison et al., 2010, Januchowski et al., 2013b).
Increased expression of ALDH1A1 in tissues from chemotherapy resistant patients tumours as well as in many drug-resistant cell lines inspired researchers to determine whether ALDH can be used as a molecular target in cancer therapy (Alison et al., 2012, Januchowski et al., 2013b). Downregulation of ALDH1 by antisense RNA in the A549 lung cancer cell line resulted in decreased ALDH1 expression and increased sensitivity of cancer cells to 4-hydroperoxycyclophosphamide (4-HC) (Moreb et al., 2000). Landen et al. showed that silencing of ALDH1A1 using siRNA in ovarian cancer cell lines resistant to taxane and platinum sensitized these cells to chemotherapy (Landen et al., 2010). It has been shown that treatment of the A549 lung cancer cell line with the differentiation agent All Trans Retinoid Acid (ATRA) led to the downregulation of ALDH1A1 and ALDH3A1 and increased sensitivity to 4-hydroperoxycyclophosphamide (4-HC) (Moreb et al., 2005). In 2011, Croker et al. showed that treatment of ALDH-positive breast cancer cells with ATRA or Diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor, sensitizes these cells to PAC and epirubicin (Croker and Allan, 2012). The effect of ATRA can result from its differentiation activity. ATRA is generally used in stem cell research because of its differentiation properties (Su et al., 2010, Tonge and Andrews, 2010). In the clinic, ATRA is used in the treatment of acute promyelocytic leukaemia (APL) (Petrie et al., 2009). ATRA treatment increases the level of intracellular retinoid acid (RA). Consequently, the levels of ALDH1A1 and ALDH3A1 are decreased and the malignant promyelocytes differentiate into mature neutrophils with enhanced sensitivity to chemotherapy. The role of DEAB in increasing the sensitivity of ALDH-positive cancer cells to chemotherapy is unclear. Because DEAB inhibits ALDH activity it has been suggested that ALDH, especially ALDH1A1, can play a direct role in drug resistance. However, the mechanism of its action in resistance to drugs other than cyclophosphamide is unknown.
Because ALDH-positive cells play a role in drug resistance in many cancers and are present in ovarian cancer tumours (Silva et al., 2011) as well as cell lines (Landen et al., 2010), we analysed our drug-resistant ovarian cancer cell lines according to different ALDH isoform expression and their association with drug resistance. Using microarray analysis of gene expression in six drug-resistant ovarian cancer cell lines, we found that cells resistant to PAC and TOP have very high expression levels of ALDH1A1. Furthermore, we were able to confirm these results using RQ-PCR, western blot, fluorescence microscopy and Aldefluor assay. Using an MTT assay, we showed that blocking ALDH1A1 by ATRA or DEAB treatment sensitizes these cells to cytostatic drugs. The mechanism responsible for cell sensitization resulted from decreased P-gp and BCRP protein levels after ATRA or DEAB treatment.
Our results confirm that ALDH1A1 plays a role in drug resistance and can be a molecular target in ovarian cancer chemotherapy. We have shown for the first time that ATRA or DEAB treatment decreases P-gp and BCRP protein levels. This leads to increased sensitivity of multidrug resistant cancer cells to cytostatic drugs.
Section snippets
Reagents and antibodies
Methotrexate (MTX), CIS, DOX, vincristine (VIN), TOP and PAC were obtained from Sigma (St. Louis, MO). RPMI -1640 medium, foetal bovine serum, antibiotic-antimycotic solution, l-glutamine, and RIPA buffer were also purchased from Sigma (St. Louis, MO). A Cell Proliferation Kit I (MTT) was purchased from Roche Diagnostics GmbH (Mannheim, Germany). Rabbit monoclonal anti-ALDH1A1 antibody (EP1933Y) was purchased from Abcam (Cambridge, UK). Rabbit anti-GADPH polyclonal Ab (FL-335), goat anti-rabbit
Microarray gene expression analysis
Based on the analysis of six drug-resistant ovarian cancer cell lines using genome-wide expression analysis by oligonucleotide microarray, we found that cell lines resistant to PAC (W1PR) and TOP (W1TR) have very high expression levels of the ALDH1A1 gene (p < 1010) (Fig. 1A). ALDH1A1 was also increased in the cell line resistant to DOX (p < 0.05); however, the expression level in this cell line was much lower. ALDH1A1 was the only ALDH isoform that was overexpressed in the investigated cell lines
Discussion
Treatment failure in ovarian cancers occurs because of low diagnosis and inherent or developed MDR during treatment. Currently, two main models of drug resistance development in cancer exist. The clonal evolution model postulates that all cells in the tumour have the same chance of becoming drug resistant because of genetic alterations (Greaves and Maley, 2012). In the CSCs model, a small population of cells in the tumour are intrinsically resistant to chemotherapy. These cells drive tumour
Conflict of interest
We declare that we have no conflicts of interest.
Acknowledgement
This study was supported by grant No. 2014/13/B/NZ5/00334 from the National Science Centre.
References (48)
- et al.
Cancer stem cells: in the line of fire
Cancer Treat. Rev.
(2012) - et al.
In vitro prediction of cytostatic drug resistance in primary cell cultures of solid malignant tumours
Eur. J. Cancer
(1993) - et al.
Cytosolic retinoid dehydrogenases govern ubiquitous metabolism of retinol to retinaldehyde followed by tissue-specific metabolism to retinoic acid
Chem. Biol. Interact.
(2003) - et al.
Retinoic acid modulates retinaldehyde dehydrogenase 1 gene expression through the induction of GADD153-C/EBPbeta interaction
Biochem. Pharmacol.
(2009) - et al.
Ovarian cancer
Lancet
(2009) - et al.
The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance
Biomed. Pharmacother.
(2013) - et al.
Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines
Biomed. Pharmacother.
(2013) - et al.
Drug transporter expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line
Biomed. Pharmacother.
(2014) - et al.
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
Eur. J. Cancer
(2015) - et al.
The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance
Chem. Biol. Interact.
(2012)
Retinoic acid directs neuronal differentiation of human pluripotent stem cell lines in a non-cell-autonomous manner
Differentiation
ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome
Am. J. Pathol.
Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose?
J. Pathol.
Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer
J. Clin. Oncol.
Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer
Clin. Cancer Res.
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal
Cancer Cell Int.
The cancer stem cell: premises, promises and challenges
Nat. Med.
Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells
Breast Cancer Res. Treat.
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer
J. Clin. Oncol.
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
Br. J. Cancer
Clonal evolution in cancer
Nature
Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells
Br. J. Cancer
MDR gene expression analysis of six drug-resistant ovarian cancer cell lines
Biomed Res. Int.
Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells
Int. J. Cancer
Cited by (74)
Pharmacological agents targeting drug-tolerant persister cells in cancer
2024, Pharmacological ResearchThe response and resistance to drugs in ovarian cancer cell lines in 2D monolayers and 3D spheroids
2023, Biomedicine and PharmacotherapyCDC45 promotes the stemness and metastasis in lung adenocarcinoma by affecting the cell cycle
2024, Journal of Translational Medicine